Can a maintenance drug stop IgA kidney disease relapse?
NCT ID NCT07604311
First seen Jun 02, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study tests whether a low dose of Nefecon (8 mg) can prevent proteinuria relapse in people with IgA nephropathy who have already responded to treatment. About 288 adults who completed 9 months of Nefecon therapy and have low protein levels will take either Nefecon or a placebo for 15 months. The goal is to see if maintenance therapy keeps the disease under control and delays kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.